IXICO PLC (GB:IXI)
LSE:IXI
Want to see GB:IXI full AI Analyst Report?
Top Page
IXICO plc
(LSE:IXI)
Select Model
Select Model
Rating:51Neutral
Price Target:
8.50 p
▼(-27.66% Downside)
Action:Reiterated
Date:02/22/26
The score is held back primarily by weak financial performance (ongoing losses and negative operating cash flow) and very bearish technicals (below key moving averages with negative MACD). A positive offset comes from supportive earnings-call guidance and order book growth, but valuation remains constrained by the company’s loss-making profile.
Positive Factors
Niche CNS imaging services
IXICO's focused business model on CNS imaging and biomarker analytics targets a specialized, high-barrier segment of clinical trials. Long-term demand for validated imaging endpoints in neurodegeneration gives a recurring project pipeline and makes expertise and regulatory-grade deliverables a durable competitive advantage.
Negative Factors
Negative operating cash flow
Persistent negative operating cash flow constrains internal funding for growth and platform development and will likely require external capital or tighter cost control. Volatile free cash flow undermines predictability of reinvestment and increases execution risk over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Niche CNS imaging services
IXICO's focused business model on CNS imaging and biomarker analytics targets a specialized, high-barrier segment of clinical trials. Long-term demand for validated imaging endpoints in neurodegeneration gives a recurring project pipeline and makes expertise and regulatory-grade deliverables a durable competitive advantage.
Read all positive factors
IXICO plc (IXI) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£14.72M
Dividend YieldN/A
Average Volume (3M)123.87K
Price to Earnings (P/E)―
Beta (1Y)0.71
Revenue Growth13.32%
EPS Growth55.07%
CountryUK
Employees81
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding218,047,590
10 Day Avg. Volume82,815
30 Day Avg. Volume123,868
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.01
Price to Sales (P/S)1.81
P/FCF Ratio-12.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£7.50M
IXICO plc Business Overview & Revenue Model
Company Description
IXICO plc provides data analytics services to the biopharmaceutical industry in the United Kingdom, Switzerland, Netherlands, Ireland, rest of Europe, the United States, and internationally. Its services include collection, analysis, management, a...
How the Company Makes Money
IXICO makes money primarily by providing services to life sciences customers (e.g., pharma/biotech companies and clinical research stakeholders) involved in clinical trials, especially CNS trials. Its revenue model is largely project- and contract...
IXICO plc Earnings Call Summary
Earnings Call Date:Dec 09, 2025
(Q4-2025)
| % Change Since: |
Next Earnings Date:Dec 08, 2026
Earnings Call Sentiment Positive
The earnings call reflects a positive outlook for IXICO plc, with strong revenue growth, a significant increase in the order book, and successful execution of strategic initiatives. While the company reported an EBITDA loss, the reduction in loss and strong financial position indicate progress towards future profitability. The company's strategic focus on CNS and partnerships suggest continued growth potential.Positive Updates
Revenue Growth and Order Book Expansion
The company reported GBP 6.5 million in revenues for the year, reflecting a 13% growth. The order book increased from GBP 13.1 million to GBP 17.7 million, showing significant growth and providing strong future revenue visibility.
Negative Updates
EBITDA Loss
The company reported a GBP 1.3 million EBITDA loss for the year, although this was a 20% reduction from the previous year.
Read all updates
Q4-2025 Updates
Positive
Negative
Revenue Growth and Order Book Expansion
The company reported GBP 6.5 million in revenues for the year, reflecting a 13% growth. The order book increased from GBP 13.1 million to GBP 17.7 million, showing significant growth and providing strong future revenue visibility.
Read all positive updates
Company Guidance
During the IXICO plc Final Results Investor Presentation for the fiscal year 2025, the company provided robust guidance, emphasizing a projected revenue growth of 15% for 2026, driven by a significant increase in their order book from GBP 13.1 million to GBP 17.7 million. The company highlighted its strategic focus on expanding in Alzheimer's and Parkinson's disease spaces, supported by their AI-driven biomarker analytics platform. IXICO has achieved a 13% revenue growth, reaching GBP 6.5 million in 2025, with a gross margin of nearly 50%. They serviced 23 clients across 37 projects, with a 1.5 book-to-bill ratio indicating healthy growth prospects. The company also highlighted its strategic goals to achieve sustainable profitability at a revenue threshold of GBP 9.5 million, while planning to innovate and build strategic partnerships, particularly in the areas of imaging biomarkers and AI technology integration.IXICO plc Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
60
Neutral
Cash Flow
50
Neutral
| Breakdown | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 6.53M | 5.77M | 6.67M | 8.64M | 9.19M |
| Gross Profit | 2.91M | 2.71M | 3.27M | 4.77M | 5.53M |
| EBITDA | -2.02M | -1.95M | -707.00K | 1.55M | 1.73M |
| Net Income | -1.65M | -2.00M | -1.18M | 1.03M | 1.51M |
Balance Sheet | |||||
| Total Assets | 13.84M | 11.19M | 12.99M | 14.65M | 14.26M |
| Cash, Cash Equivalents and Short-Term Investments | 3.54M | 1.79M | 4.03M | 5.77M | 6.68M |
| Total Debt | 179.00K | 314.00K | 387.00K | 516.00K | 597.00K |
| Total Liabilities | 2.10M | 1.72M | 1.56M | 2.16M | 2.78M |
| Stockholders Equity | 11.74M | 9.46M | 11.43M | 12.49M | 11.48M |
Cash Flow | |||||
| Free Cash Flow | -934.00K | -2.20M | -1.66M | -815.00K | -1.54M |
| Operating Cash Flow | -883.00K | -1.73M | 302.00K | 1.43M | 614.00K |
| Investing Cash Flow | -870.00K | -377.00K | -1.86M | -2.25M | -2.15M |
| Financing Cash Flow | 3.50M | -134.00K | -156.00K | -114.00K | 270.00K |
IXICO plc Technical Analysis
Negative
11.75
Price Trends
7.36
Negative
8.84
Negative
10.30
Negative
Market Momentum
-0.21
Negative
22.82
Positive
66.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:IXI, the sentiment is Negative. The current price of 11.75 is above the 20-day moving average (MA) of 6.88, above the 50-day MA of 7.36, and above the 200-day MA of 10.30, indicating a bearish trend. The MACD of -0.21 indicates Negative momentum. The RSI at 22.82 is Positive, neither overbought nor oversold. The STOCH value of 66.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:IXI.
IXICO plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | £51.63M | -1.83 | -14.65% | 2.94% | -25.43% | -155.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | £14.72M | -4.43 | -15.57% | ― | 13.32% | 55.07% | |
50 Neutral | £2.61M | -0.72 | -89.43% | ― | 91.27% | 60.98% | |
42 Neutral | £378.36M | -1.74 | -361.23% | ― | ― | ― | |
40 Underperform | £7.94M | -0.25 | -316.67% | ― | 72.17% | 79.03% | |
40 Underperform | £19.87M | -6.19 | -213.66% | ― | 13.42% | 65.63% |
* Healthcare Sector Average
GB:IXI
IXICO plc
8.63
-2.63
-23.33%
GB:AVCT
Avacta Group plc
82.00
52.00
173.33%
GB:OBD
Oxford BioDynamics
0.19
-0.13
-40.63%
GB:PYC
Physiomics
0.55
0.13
30.95%
GB:HVO
Open Orphan Plc
7.95
-9.55
-54.57%
GB:APTA
Aptamer Group Plc
0.58
0.21
59.72%
IXICO plc Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and Financing
IXICO boosts revenue and order book as it doubles down on TechBio strategy
Positive
May 19, 2026
IXICO reported a 23% rise in interim revenues to £3.9 million, driven by new contracts, extensions and higher analysis volumes in its imaging CRO business, while gross margin improved to 53% and EBITDA losses narrowed to £0.5 million. Th...
Business Operations and StrategyProduct-Related Announcements
IXICO launches upgraded AI neuroimaging platform to drive TechBio expansion
Positive
May 12, 2026
IXICO has launched version 10 of its proprietary IXI neuroimaging platform, an AI-enabled system designed specifically for neurological disease research and clinical trials. The updated release enhances image-reading precision, boosts data process...
Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
IXICO Confirms Equity Issue as Directors Back Fundraising Ahead of AIM Admission
Positive
Apr 22, 2026
IXICO plc, a specialist in AI-powered neuroscience imaging analytics for neurological drug development, has confirmed that all conditions for its previously announced first placing and subscription have been met following receipt of HM Revenue Cu...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
IXICO posts strong H1 growth and bolsters cash for AI-driven neurology push
Positive
Apr 21, 2026
IXICO reported a strong first half to 2026, with revenues expected to rise 23% to £3.9 million, driven by new contract wins, extensions and higher biomarker analysis volumes. The company also anticipates an improved gross margin of 53% and an...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
IXICO posts strong first-half growth and secures £10m to drive Tech Bio strategy
Positive
Apr 21, 2026
IXICO plc, a neuroscience imaging and biomarker analytics company, reported another period of robust growth for the six months to 31 March 2026, with revenues expected to rise 23% to £3.9m and gross margin improving to 53%, driven by new cont...
Private Placements and FinancingRegulatory Filings and ComplianceShareholder Meetings
IXICO wins shareholder backing for equity raise but faces brief delay to share admission
Neutral
Apr 16, 2026
IXICO plc said shareholders have approved all resolutions at a general meeting tied to its previously announced placings, subscription and retail offer, granting directors authority to allot new shares and implement a new non-employee sub-plan und...
Business Operations and StrategyPrivate Placements and Financing
IXICO raises £10 million through staged share issue and retail offer
Positive
Apr 7, 2026
IXICO plc has closed its recently launched UK retail offer, raising £30,320 through the issue of 379,000 new shares at 8.0 pence each, as part of a wider fundraising. Together with associated placings and a subscription priced at the same lev...
Business Operations and StrategyPrivate Placements and Financing
IXICO Opens Retail Share Offer as Part of £10.5m Fundraising Drive
Positive
Mar 31, 2026
IXICO plc has launched a retail offer in the UK for up to 6.25 million new ordinary shares at 8 pence each via the BookBuild platform, alongside previously announced placings and a subscription that together aim to raise £10 million before ex...
Business Operations and StrategyPrivate Placements and Financing
IXICO targets up to £10.5m equity raise to scale AI neurology platform
Positive
Mar 31, 2026
IXICO plans to raise up to £10.5 million through a two‑stage placing, a director subscription and a retail offer, issuing new shares at 8 pence, a small premium to the prior closing price. The first placing and director subscription of ...
Business Operations and Strategy
IXICO links AI neuroimaging platform with Medidata to boost CNS clinical trials
Positive
Mar 26, 2026
IXICO has entered a technology collaboration with Medidata, a Dassault Systèmes brand and major clinical trial solutions provider, to connect its IXI Platform with the Medidata Platform and create an integrated neuroimaging data and analysis ...
Business Operations and StrategyProduct-Related Announcements
IXICO links AI neuroimaging platform with Medidata to boost CNS clinical trials
Positive
Mar 26, 2026
IXICO plc, a specialist in AI-enabled neuroimaging and biomarker analytics for neurological clinical trials, has aligned its IXI Platform with Medidata’s clinical trial solutions to create an integrated neuroimaging data and analysis offerin...
Business Operations and StrategyProduct-Related Announcements
IXICO’s AI Imaging Platform Matches and Surpasses Gold Standard in Brain Atrophy Measurement
Positive
Feb 26, 2026
IXICO has reported new validation data showing that the automated brain volume measurement capabilities within its AI-driven IXI neuroimaging platform match, and in some measures exceed, the performance of the traditional semi-manual Boundary Shif...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.